Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Craig-Hallum Reiterates Buy Rating on Skye Bioscience (SKYE)
August 26, 2024 8:15 AM EDTCraig-Hallum analyst Albert Lowe reiterated a Buy rating and $18.00 price target on Skye Bioscience (NASDAQ: SKYE).
The analyst comments "Following the initiation of nimacimabs Phase II CBeyond obesity study, we reiterate our belief that nimacimabs novel mechanism of action as an CB1 inhibiting... More
